Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 1 2Phase NA 1Phase 4 1Phase 2/3 1

Status

Unknown 2Active not recruiting 1

Sponsor Class

OTHER 1NETWORK 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Breast 3

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1

Interventions

Trastuzumab 349Paclitaxel 310Cyclophosphamide 286Docetaxel 267Carboplatin 215Capecitabine 214Letrozole 185Fulvestrant 178Doxorubicin 166Bevacizumab 136Anastrozole 120Tamoxifen 117pertuzumab 114pembrolizumab 113Epirubicin 110exemestane 107Vinorelbine 106Gemcitabine 106Albumin-Bound Paclitaxel 92Lapatinib 84130-nm albumin-bound paclitaxel 83Radiotherapy 79palbociclib 75eribulin 73Cisplatin 69pyrotinib 66Taxes 65Everolimus 55Goserelin 50Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × EC regimen × Breast × Clear all
NCT03609047 2026-05-12

Appalaches

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Active not recruiting
366 enrolled
Breast

Breast Neoplasms

NCT05834582 2023-04-28

Neoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Unknown
60 enrolled
Breast

Triple Negative Breast Neoplasms

NCT01210768 2021-11-23

A Study of Pegylated Liposomal Doxorubicin and Cyclophosphamide in Her2-negative Stage I and II Breast Cancer Patients

TTY Biopharm

Phase 2 Unknown
254 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡